Glofitamab is a bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively.
- Mechanism
- Curator reviewed · 2 references
Glofitamab is a bispecific monoclonal antibody targeted towards CD20 surface antigens - found on B-cells - and CD3 protein complexes found on the surface of T-cells. It binds bivalently to CD20 and monovalently to CD3, thereby creating an immunological synapse that serves to recruit T-cells to CD20-expressing B-cells. This simultaneous binding allows for potent T-cell activation and proliferation which ultimately results in the lysis of the target B-cells.
- Primary indication
- Glofitamab is indicated in Canada for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma, or primary mediastinal B-cell lymphoma (PMBCL), who...Curator reviewed · 8 structured indications
- Formula / weight
- 194000.0 Da (Peptide chains only, without heavy chain C terminal lysine residues, with N terminal glutamines converted into pyroglutamates due to cyclization)
- First approval
- Canada, 2023 · United States, 2023 · European Union, 2023
- Also known as
- Glofitamab-gxbm
- Code names
- CD20-TCB · RG-6026 · RO-7082859 · WHO 11145
- Brand names
Resolves to
What you can answer from here — as of May 26, 2026
Which drugs share a target with Glofitamab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account